Scientists at the Van Andel Institute have developed a groundbreaking method for identifying and classifying subtypes of pancreatic cancer cells using unique sugar signatures known as glycans.

This innovative technique, called multiplexed glycan immunofluorescence, employs advanced software and imaging to analyze the composition of cancer cells within tumors.

The research team has refined their approach to detect glycans released into the bloodstream, making testing less invasive and more patient-friendly than traditional surgical methods.

Blood tests for glycans are not only quicker but also more cost-effective, enhancing the overall patient experience.

This advancement has the potential to lead to earlier and more accurate diagnoses of pancreatic cancer, which is often asymptomatic in its early stages.

According to Dr. Brian Haab, the study's corresponding author, this method will enable physicians to tailor treatments more effectively by revealing the specific subtypes of cancer cells present in a tumor.

The study, co-authored by Braelyn Binkowski and Zachary Klamer, is supported by a diverse group of collaborators from various institutions.

The research continues to validate this method and aims to discover glycan signatures for rarer cell types and other gastrointestinal cancers.

The team is also exploring the potential to apply this method to detect and characterize other gastrointestinal cancers.

Pancreatic cancer is notoriously difficult to detect early, with only 15% of cases diagnosed in time for surgical intervention due to the lack of noticeable symptoms.

While this method is not yet available in clinical labs, researchers are optimistic that it could become a standard diagnostic tool for pancreatic cancer within a few years.